Year 2017 Vol. 25 No 4




Central City Clinical Hospital1,
National Center for Medicines, Medical Devices and Medical Equipment Expertise2,
Kazakhstan Research Institute of Oncology and Radiology 3,
Kazakhstan National Medical University named after S.D.Asfendilyarov4,
The Republic of Kazakhstan

Objectives. To study epidemiological aspects of colorectal cancer in the Republic of Kazakhstan for 2004-2014 years.
Methods. A retrospective statistical analysis of the epidemiological status of colorectal cancer in Kazakhstan for 11 years has been carried out (standardized rate indicators of WHO World per 100 000 population and intensive values of morbidity, mortality and distribution according to stages, age, sex), as well as the results of the population-based colorectal screening from 2011 to year 2014 are presented.
Results. The statistical data on the morbidity, distribution by sex and age of colorectal cancer in the Republic of Kazakhstan testify to its stable ongoing growth presented in the article. However, the main challenge is an evident demonstration of the effectiveness of colorectal screening; the growth of the number of patients with cancer stage I-II from 29,7% in 2008 to 48,7% in 2014 and the reduction of the number of patients with cancer stage IV from 21,2 % in 2008 to 15,7% in 2014. Since 2011 the improvement of colorectal screening has been observed, that manifested in the increasing of "detection" of colon cancer, rate to the number of coverage incidence from 0.02 in 2011 to 0,05 in 2014 and the increasing of the proportion with I-II stages, rate of the diagnosed cases from 71,4% in 2011 to 81,1% in 2014.
Conclusion. According to the obtained results the incidence of colorectal cancer is increasing from year to year, as well as the mortality caused by this disease. The population colorectal screening introduced in 2011 in the Republic of Kazakhstan aimed to identify pre-cancer and cancer in the early stages shows quite optimistic results within the recent period (2011-2014.).

Keywords: colorectal cancer, screening, colon, rectum, epidemiology of colorectal cancer, morbidity, mortality
p. 394-403 of the original issue
  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase N 11 [Electronic resource]. Lyon, France: International Agency for Research on Cancer; 2013. Available from:, accessed on day/month/year.
  2. Okeanov AE, Moiseev PI, Levin LF, Sukonko OG, red. Statistika onkologicheskikh zabolevanii v Respublike Belarus' (2004-2013) [Statistics of oncological diseases in the Republic of Belarus (2004-2013)] = Statistics of cancer diseases. Minsk, RB; 2014. 382 p.
  3. 2008 WGO Practice Guidelines, World Gastroenterology Organisation [Electronic resource]. Available from:
  4. Allison JE, Feldman R. Cost benefits of hemoccult screening for colorectal carcinoma. Dig Dis Sci. 1985 Sep;30(9):860-65.
  5. Barry MJ, Mulley AG, Richter JM. Effect of workup strategy on the cost-effectiveness of fecal occult blood screening for colorectal cancer. Gastroenterology. 1987 Aug;93(2):301-10.
  6. Wagner JL, Duffy B, Wadhwa S, et al. Costs and effectiveness of colorectal cancer screening in the elderly. Washington, DC: U.S. Government Printing Office; 1990. 56 p.
  7. Wagner JL, Herdman RC, Wadhwa S. Cost effectiveness of colorectal cancer screening in the elderly. Ann Intern Med. 1991 Nov 15;115(10):807-17.
  8. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev. 2011;33:88-100. doi: 10.1093/epirev/mxr004.
  9. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009 Nov-Dec;59(6):366-78. doi: 10.3322/caac.20038.
  10. Binefa G, Rodríguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014 Jun 14;20(22):6786-808. doi: 10.3748/wjg.v20.i22.6786.
  11. West NJ, Boustiere C, Fischbach W, Parente F, Leicester RJ. Colorectal cancer screening in Europe: differences in approach; similar barriers to overcome. Int J Colorectal Dis. 2009;24:731. doi: 10.1007/s00384-009-0690-6.
  12. Goulard H, Boussac-Zarebska M, Ancelle-Park R, Bloch J. French colorectal cancer screening pilot programme: results of the first round. J Med Screen. 2008;15(3):143-48. doi: 10.1258/jms.2008.008004.
  13. Butruk E, Regula J, Polkowski M, Rupinski M, Przytulski K. National colorectal cancer screening programme in Poland. Endoscopy. 2002;34(11):939-40.
  14. Regula J, Zagorowicz E, Butruk E. Implementation of a national colorectal cancer screening program. Curr Colorectal Cancer Rep. 2006;2:25-29. doi: 10.1007/s11888-006-0014-y.
  15. Smith RA, Manassaram-Baptiste D, Brooks D, Cokkinides V, Doroshenk M, Saslow D, et al. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2014 Jan-Feb;64(1):30-51. doi: 10.3322/caac.21212.
Address for correspondence:
050012, Republic of Kazakhstan, Almaty, Tole bi str., 94,
Kazakh National Medical University named after S.D. Asfendiyarova,
department of postgraduate education (doctorate, postgraduate study, magistracy)
Tel.: 77077613019,
Aynur B. Mansurova
Information about the authors:
Abdullayev M.S. MD, Professor, Director of Central City Clinical Hospital of Almaty.
Nurgaziev K.S. MD, Head of Department of Strategic Development and Legislation Improvement, National Center for Medicines, Medical Devices and Medical Equipment Expertise
Zhylkaydarova A.Z. PhD, Head of specialized consultative and diagnostic department of Kazakhstan Research Institute of Oncology and Radiology.
Mansurova A.V. Applicant for Doctors degree of Kazakhstan National Medical University.
Contacts | ©Vitebsk State Medical University, 2007-2023